Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;37(12):4831-4847.
doi: 10.1007/s12325-020-01512-w. Epub 2020 Oct 15.

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

Erica Velthuis  1 , Julie Hubbard  2 , Salvatore Longobardi  3 , Thomas D'Hooghe  4   5   6
Affiliations

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

Erica Velthuis et al. Adv Ther. 2020 Dec.

Erratum in

Abstract

Background: Recombinant human follitropin alfa (r-hFSH) is used for ovarian stimulation as part of medically assisted reproduction. There is a risk for ovarian hyperstimulation syndrome (OHSS) with r-hFSH treatment, and an increased risk for thromboembolic events in the presence of pregnancy with OHSS.

Objectives: To report the frequency of OHSS and thromboembolism with originator follitropin alfa (GONAL-f) based on the Global Safety Database of Merck KGaA, Darmstadt, Germany and a systematic review of published data.

Data sources: Reports of OHSS and thromboembolism were obtained from the Global Safety Database of Merck KGaA, Darmstadt, Germany from 20 October 1995 to 19 October 2018. The systematic review was based on MEDLINE and Embase searches from inception to 19 October 2018.

Study eligibility criteria: Patients receiving GONAL-f for ovulation induction or ART, with a starting dose within the range included in the prescribing information and providing information on the occurrence of OHSS and/or thromboembolism.

Study appraisal and synthesis matches: In the Global Safety Database of Merck KGaA, Darmstadt, Germany there were an estimated 16,525,975 treatment cycles since 20 October 1995; 1110 reported cases of OHSS and 80 reported cases of thromboembolic events (reporting rates 6.7 and 0.48 per 100,000 treatment cycles, respectively). The systematic review identified 45 studies (5186 patients exposed to GONAL-f; 5240 treatment cycles). There were 272 reports of OHSS (5190 [5.19%] per 100,000 treatment cycles), including 10 cases of severe OHSS (191 [0.19%] per 100,000 treatment cycles).

Limitations: There may be the potential for under-reporting of safety outcomes in the literature, and under-reporting is a well-known phenomenon in spontaneous reporting databases.

Conclusion and implications of key findings: Our analyses demonstrate low rates of OHSS and thromboembolism with GONAL-f.

Keywords: GONAL-f; Ovarian hyperstimulation syndrome; Safety; Thromboembolism; Women’s health; r-hFSH.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA diagram. OHSS ovarian hyperstimulation syndrome, PD pharmacodynamic, PK pharmacokinetic
Fig. 2
Fig. 2
Risk of bias assessment
See this image and copyright information in PMC

References

    1. Merck KGaA. GONAL-f 450 IU (33 mcg) pen. 2018. https://www.medicines.org.uk/emc/medicine/14384. Accessed 2019.
    1. European Medicines Agency. Ovaleap. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/ovaleap. Accessed 2019
    1. European Medicines Agency. Bemfola. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola. Accessed 2019
    1. Magnusson A, Kallen K, Thurin-Kjellberg A, Bergh C. The number of oocytes retrieved during IVF: a balance between efficacy and safety. Hum Reprod. 2018;33(1):58–64. doi: 10.1093/humrep/dex334. - DOI - PubMed
    1. Vloeberghs V, Peeraer K, Pexsters A, D'Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):691–709. doi: 10.1016/j.bpobgyn.2009.02.006. - DOI - PubMed

Publication types

MeSH terms

Substances